Evidence map›Paper›PMID 31407253›Full record

ArticleJournal of gastrointestinal cancer2020

CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients.

Shirin Eyvazi, Amir Mahdi Khamaneh, Vahideh Tarhriz, Mojgan Bandehpour, Mohammad Saeid Hejazi, Amir Taher Eftekhar Sadat, Bita Sepehri

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shirin EyvaziBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Amir Mahdi KhamanehDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahideh TarhrizMolecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mojgan BandehpourDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Saeid HejaziMolecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Amir Taher Eftekhar SadatPathology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Bita SepehriLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. B.sepehri98@gmail.com.
Tabriz University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences 294
6 · The paper itself

Abstract

purposeGastric cancer is an aggressive disease which is the fourth prevalent malignancy in the world. Beside the genetic factors, epigenetic alterations such as promoter CpG island hyper methylation are involved in the emergence of gastric cancer. Herein, we investigated the methylation status of CDH11, EphA5, and HS3ST2 genes in patients with and without gastric adenocarcinoma for the first time.

methodsIn the study 40 paraffin-embedded tissue sections from gastric adenocarcinoma patients and 40 specimens from patients with functional dyspepsia were taken. DNA extraction was performed using a modified salting out method. Epizen DNA methylation kit was used to the bisulfite DNA conversion. The methylation status of CDH11, EphA5, and HS3ST2 genes were analyzed by methylation-specific PCR (MSP) technique.

resultsAmong the 80 specimens, 71 DNA samples were achieved (34 gastric adenocarcinoma patients and 37 control patients). The results showed that CDH11, EphA5, and HS3ST2 genes are methylated in 28 (82.45%), 19 (55.88%), and 26 (76.47%) of 34 DNA samples from gastric adenocarcinoma patients, respectively, whereas, these genes are methylated in 7 (18.91%), 9 (24.32%) and 7 (18.91%) of 37 samples from noncancerous patients, respectively. Statistical analyses using a chi-squared test showed that there is a statistically significant difference in methylation level of CDH11, EphA5, and HS3ST2 genes between gastric cancer and uncancerous patients (p < 0.05).

conclusionTo the best of our knowledge, this is the first report on methylation of CDH11, EphA5, and HS3ST2 promoters' in gastric adenocarcinoma patients using MSP. Identification of novel cancer-related molecular mechanisms can be useful in detection of new treatment strategies.

Indexed as

CpG IslandsDNA MethylationAdenocarcinomaAgedAged, 80 and overBiomarkers, TumorCadherinsCase-Control StudiesDNA, NeoplasmFemaleHumansMaleMiddle AgedPromoter Regions, GeneticReceptor, EphA5Stomach NeoplasmsBiomarkers, TumorCadherinsDNA, NeoplasmEPHA5 protein, humanosteoblast cadherinReceptor, EphA5SulfotransferasesCDH11EphA5Gastric adenocarcinomaHS3ST2Hyper methylationMSP

Identifiers

PMID31407253
OpenAlexW2967909164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.